Incannex Healthcare Inc. (IXHL) has received FDA authorization to proceed with the Phase 3 stage of its RePOSA clinical trial, assessing IHL-42X, its lead drug candidate for obstructive sleep apnea - OSA.
This condition affects approximately one billion people globally and currently lacks an approved oral therapy.
The Phase 3 trial will commence in the U.S. immediately after Phase 2 concludes, utilizing the same infrastructure and vendors to enhance speed and reduce costs. Around 20 existing U.S. trial sites will continue, with 10 more to be added. The trial will last 12 months and evaluate IHL-42X's safety and efficacy against both placebo and its individual drug components—dronabinol and acetazolamide.
CEO Joel Latham emphasized the significance of this milestone, stating that IHL-42X could be the first FDA-approved oral treatment for OSA, positioning Incannex for strong commercial impact. He noted the streamlined U.S.-only design and retained operational continuity as key advantages, with Phase 2 topline data expected soon.
Thursday, IXHL closed at $0.22, down 4.39%, before rising 1.77% in after-hours trading to close at $0.2239 on the NasdaqGM.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.